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Abstract
Background: The incidence of Cholangiocellular Carcinoma (CCA) is increasing in the western world. The tumour
has a high proportion of desmoplastic stroma and is correlated with a worse prognosis when cancer associated
myofibroblasts (CAFs) are present. Recent studies showed promising results after liver transplantation (LTx) in
non-resectable early stage CCA. Mycophenolic acid (MPA) and the mTor inhibitor Everolimus are used to prevent
organ rejection but recently were shown to exhibit an antiproliferative effect on CCA-cells. Little is known about the
influence of immunosuppressive drugs on tumour cell proliferation and migration after paracrine stimulation by
CAFs. Moreover, it is still unknown, which signaling pathways are activated following these specific cell-cell interactions.
Methods: CCA cell lines HuCCT1 and TFK1 were utilized for the study. CAFs were derived from resected CCA cancer
tissue. Cell viability was measured by the crystal violet assay and tumour cell invasion was quantified using a modified
co-culture transmigration assay. Semiquantitative cytokine-expression was measured using a cytokine-array. Protein
expression and phosphorylation of ERK, STAT3 and AKT was determined by Western-blot analysis.
Results: CCA cells treated with MPA exhibited a dose related decrease in cell viability in contrast to Cyclosporine A
(CSA) treatment which had no effect on cell viability. Everolimus significantly inhibited proliferation at very
low concentrations. The pro-invasive effect of CAFs in co-culture transmigration assay was significantly
reduced by Everolimus at a concentration of 1nM (p = 0.047). In contrast, MPA and CSA showed no effect on
tumour cell invasion. Treatment of CAFs with 1nM Everolimus showed a significant reduction in the expression of IL 8,
IL 13, MCP1, MIF and Serpin E1. CCA-cells showed significant increases in phosphorylation of ERK, STAT3 and AKT
under the influence of conditioned CAF-media. This effect was suppressed by Everolimus.
Conclusions: The secretion of proinflammatory cytokines by CAFs may lead to increased activation of JAK/STAT3-, ERK-
and AKT-signaling and increased migration of CCA-cells. Everolimus abrogates this effect and inhibits proliferation of
CCA-cells even at low concentrations.
LTx for non-resectable early stage CCA is currently performed in several clinical studies. Consistent with a role for
common immunosuppressants in inhibiting tumour cell-proliferation and -invasion, our study indicates that a
combination of standard therapies with Everolimus and MPA is a promising therapy option to treat CCA following LTx.
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Background
The incidence of cholangiocellular carcinoma (CCA) has
been increasing over the past decades [1]. Currently sur-
gical resection is the only curative treatment option.
However, in most cases the tumour is non resectable at
the time of diagnosis leaving only palliative treatment
options which have low survival rates [2–5]. Recently,
there has been a renewed interest in performing ortho-
topic liver transplantation (OLTx) as an alternative ap-
proach to treat CCA. Published results from the latest
clinical studies have indicated 5-year survival rates be-
tween 71 and 82 % for non-resectable early stage CCA
[6]. Therefore OLTx has become a feasible treatment op-
tion and could offer better survival rates than palliative
therapy [7]. In the above mentioned studies the recipi-
ents were treated with neo-adjuvant therapy based on
the Mayo protocol [8, 9]. In this protocol only patients
with locally non-resectable early stage CCA or arising
CCA in the setting of underlying primary sclerosing
cholangitis (PSC) were included.
The administration of immunosuppressive drugs in
cancer patients has generally been avoided due to the
suspected risk of tumour progression when supressing
the human immune system. However, over the last
decade several substances which were classically used as
immunosuppressive drugs have elicited beneficial anti-
cancer effects. One of the promising agents for medi-
ating immunosuppression and anti-cancer effects fol-
lowing OLTx is rapamycin, which inhibits mTOR
protein kinase activity. Activation of mTOR leads to
increased tumour progression [10] and expression of
pro-angiogenic growth factors [11] by two distinct
complexes: mTOR complex 1 (mTORC1) and mTOR
complex 2 (mTORC2). Functionally mTORC1 affects
cell growth by regulating mRNA translation and ribo-
some biogenesis and negatively regulates AKT activa-
tion. mTORC2 activates AKT and phosphorylation of
downstream effectors promotes cell survival, proliferation
and metabolism. It has previously been observed that
mTOR inhibitors like Rapamycin reduce CCA progression
and enhance long-term survival in patients with inoper-
able CCA [12–15]. A second recently developed mTOR
inhibitor, Everolimus, is endowed with a more favourable
pharmacokinetic profile [16, 17] and targets primarily
mTORC1 inhibiting cell cycle progression, survival, and
angiogenesis [18].
The immunosuppressive agent Mycophenolic acid
(MPA) is used to prevent acute graft rejection after
transplantation. MPA inhibits inosine monophosphate
dehydrogenase (IMPDH), which leads to inhibition of de
novo synthesis of guanosine nucleotides [19–22]. This is
the principle mechanism by which the prodrug of MPA,
mycophenolate mofetil (MMF) blocks T and B lympho-
cyte proliferation and clonal expansion, and prevents the
generation of cytotoxic T cells and other effector T cells.
Furthermore, several studies showed that IMPDH can
function as a sequence-specific DNA-binding transcrip-
tion factor [23] by binding and repressing histone genes
and E2F, the master driver of the G1/S transition of the
cell cycle. Since IMPDH and particularly IMPDH2 are
significantly up-regulated in many tumour cells, [24, 25]
they are potential targets for anti-cancer strategies.
Several studies have shown MMF to inhibit cancer cell
proliferation and induce apoptosis in vitro and in vivo
[26–31]. Mechanisms for this anticancer effect are pos-
tulated to be mediated through activation of the key
tumour suppressor molecule p53 [32] by IMPDH and
its ability to inhibit the surface expression of some
integrins [33].
Several studies have reported a strong impact of
tumour-stroma interaction and extracellular matrix pro-
teins in the development of CCA. Cancer associated fi-
broblasts (CAFs) have been shown to be a key player in
creating an inflammatory microenvironment which
stimulates invasion of tumour cells [34]. Increased
immunohistochemical staining of α-smooth muscle
actin (α-SMA) in CAFs has been shown to correlate
with shorter survival times as well as a larger tumour
size in surgically resected intrahepatic CCA [34–36].
Therefore, agents that inhibit or reduce paracrine in-
teractions between CCA tumour cells and CAFs leading
to an inhibition of tumour invasion and proliferation can
potentially have therapeutic application in anticancer
treatment of CCA.
In this study we have examined in vitro, the anticancer
properties of the two immunosuppressive agents,
Everolimus and MPA. With a view to a possible applica-
tion of these drugs following OLTx, the effect on CCA
tumour cell-proliferation and invasion was compared with
the well established immunosuppressive drug Cyclospor-
ine A (CSA). Special focus was given to possible interac-
tions between CAFs and CCA-tumour cells in stimulating
tumour cell-proliferation, invasion and a possible effect of
the drugs in the inhibition of paracrine interactions.
Methods
Cells
The CCA cell-lines HuCCT-1 (intrahepatic/distal tumour)
and TFK-1 (extrahepatic/hilar tumour) were used. Cells
were obtained from Cell Bank RIKEN Bio Resource
Centre in Japan.
CAFs were obtained from tumour resections following
patient’s informed consent and the use of patient’s
tumour tissue was approved by the local ethics com-
mittee of the “Medizinische Fakultät der Christian-
Albrechts-Universität zu Kiel” (AZ 110/99). Directly
after resection, liver tissue was cut into small pieces and
cultured in Dulbecco’s Modified Eagle Media (DMEM).
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Adherent cells were collected and characterized by im-
munocytochemical staining for α-SMA, Vimentin and
pan-cytokeratin marker. Negative control stained cells
were counterstained with hemalaun/eosin.
Cell growth/viability assay
Cells were seeded into 96-well plates (tumour cells
1×104 cells/well; CAF’s 2,5×103 cells/well) in DMEM
supplemented with 10 % FCS. One day later the media
was replaced by fresh DMEM plus 10 % FCS containing
different concentrations of CSA, Everolimus and MPA.
Cell viability was measured after 24, 48 and 96 h using
Crystal violet assay and compared to the viability of the
non treated tumour cells and CAFs. The calcineurin in-
hibitor CSA, which is used as a common immunosuppres-
sive drug following OLTx, was used as a reference. The
drug was selected as a control, because no inhibitory effect
on tumour proliferation and migration was expected.
Migration assay
Migration of untreated tumour cells, tumour cells co-
cultured with CAFs and with MPA, Everolimus and CSA
treatment were analysed. The analysis was performed
using a modified Boyden chamber assay, using cell cul-
ture inserts for 24-well plates containing membranes
with 8 μm pore size. In the CAF/tumour cell co-culture,
CAF’s were seeded in a density of 3×104cells/well in
DMEM in the lower compartment. After overnight at-
tachment, media was replaced and matrigel-coated in-
serts were added. Afterwards 5×104 tumour cells were
seeded in the upper chamber and Everolimus, CSA or
MPA were added directly into the medium. An incuba-
tion time of 30 h was used to minimize the bias of pro-
liferation in this assay. The examination area for the cell
count was 0,35 mm2. For further analysis, the cell count
of migrated cells without CAFs in a co-culture was set
as 1. For comparison of treated and non-treated co-
culture groups an index was calculated.
Western blot analysis
A fluorescent read-out was used to detect drug target
proteins for mTOR and calcineurin in both tested cell
lines TFK-1 and HUCCT-1 after 24, 48 and 96 h. These
time points corresponded to the cell viability measure-
ment after treatment with the tested drugs. To study the
effects of CAFs on the JAK/STAT, AKT- or ERK-
pathway, conditioned CAF-media in which fibroblasts
had grown for 48 h, was added to DMEM-media and
compared to the activation of the specific pathways
under DMEM-media without CAF-media. The influence
of Everolimus on the activity of the JAK/STAT-, AKT-
and ERK-pathway was investigated by measuring STAT/
pSTAT, AKT/pAKT as well as ERK/pERK for tumour
cells that were treated with Everolimus. Specifically, cells
were seeded into 6-well plates and incubated for 24 h at
a temperature of 37 °C in DMEM supplemented with
10 % FCS or 0 % FCS. One day later the media was re-
placed by fresh DMEM with or without conditioned
CAF-media. To investigate the effect of Everolimus on
tumour cells, the drug was incubated in the presence of
tumour cells for 24 h. To investigate the paracrine effect
of Everolimus, CAFs were treated with 1 μM Everolimus
for 24 h prior to stimulation of tumour cells with the
Everolimus-treated CAF-media. As a reference, cells
were stimulated with 100 ng/ml hIL-6. Cells in 6-well
plates were lysed by RIPA-lysis-buffer followed by
protein extraction using ultrasound sonication. The
protein assay was done by DC-protein assay (Bio-Rad
Laboratories©, Munich, Germany). Protein concentra-
tions were adjusted and diluted by RIPA-lysis-buffer.
Samples were then loaded in duplicate and separated by
SDS-PAGE and transferred to FL-membranes (Novex, Life
Technologies, Carlsbad, CA). The membranes were
blocked in 5 % BSA in TBS, then incubated with primary
antibodies for pSTAT3/STAT3, pERK/ERK, pAKT/AKT,
ß-Actin and drug-target protein specific antibodies for
mTOR and calcineurin (IRDye® 800 CW Goat anti-Rabbit
IgG, IRDye® 680 RD Goat anti-Mouse IgG). The mem-
branes were washed three times for 10 min in TBST and
then probed with goat anti-mouse/rabbit IR-Dye 670 or
800cw labelled secondary antisera (LI-COR, Bad
Homburg, Germany) for 1 h at room temperature.
Membranes were imaged using a LiCOR Odyssey
scanner. Regions of interest were manually placed
around each band, which returned near-infrared fluor-
escent values of raw intensity. Intra-lane background
values were subtracted using Odyssey 3.0 analytical
software (LiCor, Lincoln, NE).
Cytokine expression assay
A possible alteration in cytokine expression for Everolimus
treated CAFs was measured by a human cytokine array
system (Proteome Profiler™ Array, Human Cytokine Array
Panel A, R&D Systems Europe, Ltd., UK & Europe). Ex-
pression of the following cytokines were determined: CD
40 Ligand, G-CSF, GM-CSF, CROa, I-309, sICAM-1, IFN-
γ, IL-1a, IL-1ß, IL-1ra, IL-2, IL-6, IL-8, IL-13, IL-16, IL-17,
IL-17E, IL-23, MCP-1, MIF, Serpin E1. CAFs were treated
with 1 μmol Everolimus for 10 min. The Everolimus
treated media and a sample of untreated CAFs-media
were incubated with 15 μL of reconstituted Human
Cytokine Array Panel A Detection Antibody Cocktail
for one hour. Subsequently the incubated media was
added to a buffer-prepared 4-Well Multi-dish and in-
cubated for 12 h. After blotting the media/antibody
solution on specific membranes, these membranes were
exposed to an X-ray film to visualise the extent the differ-
ent cytokines expression. Changes of cytokine expression
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between Everolimus treated and untreated CAFs-media
were measured by densitometry (Image J 1.41o, National
Institute of Health, USA).
Statistical analysis
Data was analysed using SPSS for Macintosh (Version
21.0) software (IBM Corporation, New York, USA). All
metric parameters are expressed as total numbers (%) or
mean ± standard deviation (SD). Comparison between
groups was made using an unpaired t-test. A p-value <0.05
was considered statistically significant.
Results
Characterization and immunocytochemical staining of
collected CAFs
Adherent cells stained strongly for both α-smooth
muscle actin (Fig. 1a) and Vimentin (Fig. 1b) and were
negative for the pan-cytokeratin marker KL-1 (Fig. 1c).
Hemalaun eosin staining of adherent cells displayed
elongated morphology characteristic of fibroblast cells
(Fig. 1d).
Effect of immunosuppressive and cytostatic agents on
tumour cell-viability
To study the effect of the different drugs, we first treated
the two tumour cell lines and CAFs with variable con-
centrations of CSA, Everolimus and MPA. The target
proteins mTOR and calcineurin were detected by fluor-
escent Western-Blot analysis in both tested cell lines,
TFK-1 and HUCCT-1, at the different time points of
cell-viability measurement (Fig. 2). Analysis of cell viabil-
ity revealed that MPA induced a strong dose and time
dependent effect on tumour cell lines (Fig. 3a). For
HUCCT-1 and TFK-1 cells a significant lower viability
was measured for every tested dosage at 24 h, 48 h and
96 h of treatment except the lowest treatment dose of
0.5 μM for 24 h (p < 0.05, unpaired t-test). Compared to
MPA, Everolimus showed a weaker dose and time
dependent effect although after 96 h of treatment this
difference became less obvious (Fig. 3b). A significant
lower viability was nevertheless measured for both tested
cell lines with Everolimus treatment for every tested
dosage at 24 h, 48 h and 96 h of treatment (p < 0.05, un-
paired t-test). CSA showed no significant influence on
cell viability, even at high concentrations (Fig. 3c). For
CAFs a dose and time dependent effect was observed
only for the treatment with Everolimus. A significant
lower viability was measured with 0.5 nM, 5 nM and
50 nM at 48 h and 96 h of treatment (p < 0.05, un-
paired t-test) (Fig. 3d). MPA and CSA showed no sig-
nificant influence on cell viability of CAFS in a dose
dependent manner except for the test dosage of 10 μM at
24 h with MPA treatment (p < 0.05, unpaired t-test)
(Fig. 3e and f).
Fig. 1 a-d. Immunocytochemical staining of collected CAFs. Immunocytochemical staining for α-smooth muscle actin (a), Vimentin (b),
pan-cytokeratin marker (c) and HE (d) as negative control group
Heits et al. BMC Cancer  (2016) 16:322 Page 4 of 12
Effect on tumour-cell migration after treatment with
Everolimus, MPA and CSA in co-culture
We next analysed CAF-mediated migratory activity of
TFK-1 and HuCCT-1 in a co-culture system. Boyden
chamber assays demonstrated that isolated CAFs stimu-
lated the migratory and proliferative potential of the
intrahepatic CCA cell lines. We noticed a significantly
higher migratory activity for both CCA-cell lines with
CAFs in co-culture (TFK-1/CAFs: 6.3 (±3.5) cells/
0.35 mm2, p = 0.00014; HuCCT1/CAFs: 29.8 (±1) cells/
0.35 mm2, (p = 0.001) compared to the CCA-cell line
monoculture (TFK-1: 0.5 (±1.7) cells/0.35 mm2;
HuCCT1: 5.3 (±0.4) cells/0.35 mm2). We then per-
formed the test in the presence of Everolimus, MPA
or CSA. A dosage of 0.25 μM was used for CSA, 0.1 μM
was used for MMF and 1 nM was used for Everolimus
treatment. Compared to the untreated co-culture (TFK-1/
CAFs: 21.3 (±2) cells/0.35 mm2; HuCCT1/CAFs: 51.3
(±8.9) cells/0.35 mm2), the Everolimus treated co-culture
showed a significant inhibition of tumour cell migration
for both treated CCA-cell-lines (TFK-1/CAFs: 12.3, (±2)
cells/0.35 mm2, p = 0.000013; HuCCT1/CAFs: 36.8, (±5.3)
cells/0.35 mm2, p = 0.009) (Fig. 4a). For MPA and CSA no
significant effect was measured (Fig. 4b).
Western blot analysis determining cell activation and
presence of drug target proteins
After stimulating cancer cells with conditioned fibroblast
media, the level of phosphorylated STAT3, AKT and
ERK were observed to increase noticeably in the TFK-1
cell line. In the HuCCT-1 cell line only an up-regulation
of phosphorylated STAT3 was observed. Highest levels
were detected fifteen minutes after stimulation with con-
ditioned media (Fig. 5a, b). Pre-treatment of TFK-1 cells
with 1 μM Everolimus for 24 h followed by stimulation
with conditioned CAF-media resulted in a decrease of
STAT3-phosphorylation and slight decrease in AKT-
phosphorylation. A decrease in phosphorylated ERK-
kinase was not noticed for this cell line (Fig. 6a). With
the HUCCT-1 cell line we only observed a decrease of
the STAT3-phosphorylation with 1 μM Everolimus pre-
treatment but surprisingly no decrease in levels of phos-
phorylated ERK- and AKT-kinase was observed (Fig. 6b).
Treatment of the tumour cell lines with Everolimus-
treated CAFs conditioned media showed no effect on
phosphorylation status for either of the two cell lines.
Analysis of cytokine expression by cholangiocarcinoma-
CAFs
Having observed a significant inhibition of tumour cell
migration for the Everolimus treated co-culture, the in-
fluence of Everolimus treatment on CAF-cytokine ex-
pression was measured using the human cytokine array
to investigate the influence of the drug on paracrine
tumour-cell stimulation. A significant lower cytokine ex-
pression for Everolimus treated CAFs was detected by
densitometric evaluation. This significant lower cytokine
expression was measured after 10 min of treatment with
1 μM Everolimus for cytokines IL-8 (p = 0.035), IL-13
(p = 0.0012), MCP-1 (p = 0.035), MIF (p = 0.03) and
Serpin E1 (p = 0.02) (Fig. 7). The expressions of the other
16 tested cytokines were not significantly affected.
Discussion
We investigated the influence of primary cultured CAFs
obtained from CCA-tumour resections on tumour
migration and proliferation of an intrahepatic and extra-
hepatic CCA cell line. We specifically analysed the influ-
ence of the mTOR-inhibitor Everolimus and MPA in a
human in-vitro CAF-CCA tumour cell co-culture model.
The major finding of the study was that a concurrent
inhibition on tumour cell proliferation and migration oc-
curs following Everolimus treatment. Several independ-
ent observations indicate that inhibition of migration
was likely mediated by a decrease in paracrine stimula-
tion of tumour cells by CAFs. Firstly, no changes in
phosphorylated STAT3, AKT and ERK where observed
in CCA cell lines at concentration which reduced migra-
tion. Secondly, Everolimus treatment of CAFs resulted
in a decrease in CAF-secreted cytokines which are
known to promote tumour cell migration. The rational
for this project was to test whether immunosuppressive
drugs that are crucial to successfully treat patients who
underwent liver transplantation can also be of use in
anti-cancer treatment. The results of the study open new
possibilities for integrating agents that were traditionally
Fig. 2 Fluorescence Western-blot for target proteins. Fluorescence Western-blot for the detection of the target proteins mTOR for Everolimus and
calcineurin for CSA after 24 h (a), 48 h (b) and 96 h (c) in DMEM solution
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Fig. 3 (See legend on next page.)
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Fig. 3 a Proliferation of HuCCT-1 and TFK-1 under treatment with MPA, *p <0.05, unpaired t-test. Tumour cells were treated with DMEM plus
10 % FCS containing different concentrations of MPA. Cell viability was measured after 24, 48 and 96 h using Crystal violet assay (blue line: 24 h
of treatment with different drug concentrations of MPA, reed line: blue line: 48 h of treatment with different drug concentrations of MPA, green
line: 96 h of treatment with different drug concentrations of MPA). b Proliferation of HuCCT-1 and TFK-1 under treatment with Everolimus, *p <0.05,
unpaired t-test. Tumour cells were treated with DMEM plus 10 % FCS containing different concentrations of Everolimus. Cell viability was measured
after 24, 48 and 96 h using Crystal violet assay (blue line: 24 h of treatment with different drug concentrations of Everolimus, reed line: blue line: 48 h
of treatment with different drug concentrations of Everolimus, green line: 96 h of treatment with different drug concentrations of Everolimus).
c Proliferation of HuCCT-1 and TFK-1 under treatment with CSA. Tumour cells were treated with DMEM plus 10 % FCS containing different
concentrations of CSA (blue line: 24 h of treatment with different drug concentrations of CSA, reed line: blue line: 48 h of treatment with
different drug concentrations of CSA, green line: 96 h of treatment with different drug concentrations of CSA). d Proliferation of CAFs under
treatment with MPA, *p <0.05, unpaired t-test. CAFs were treated with DMEM plus 10 % FCS containing different concentrations of MPA. Cell
viability was measured after 24, 48 and 96 h using Crystal violet assay (blue line: 24 h of treatment with different drug concentrations of
MPA, reed line: blue line: 48 h of treatment with different drug concentrations of MPA, green line: 96 h of treatment with different drug
concentrations of MPA). e Proliferation of CAFs under treatment with Everolimus, *p <0.05, unpaired t-test. CAFs were treated with DMEM
plus 10 % FCS containing different concentrations of Everolimus. Cell viability was measured after 24, 48 and 96 h using Crystal violet assay
(blue line: 24 h of treatment with different drug concentrations of Everolimus, reed line: blue line: 48 h of treatment with different drug
concentrations of Everolimus, green line: 96 h of treatment with different drug concentrations of Everolimus). f Proliferation of CAFs under
treatment with CSA. CAFs were treated with DMEM plus 10 % FCS containing different concentrations of CSA. Cell viability was measured
after 24, 48 and 96 h using Crystal violet assay (blue line: 24 h of treatment with different drug concentrations of CSA, reed line: blue line:
48 h of treatment with different drug concentrations of CSA, green line: 96 h of treatment with different drug concentrations of CSA)
Fig. 4 a Modified co-culture transmigration assay for HuCCT-1/CAF and TFK-1/CAF treated with Everolimus. *Non-treated co-culture vs. monoculture,
#With 1 nM Everolimus treated co-culture vs. non treated co-culture: p <0.05, unpaired t-test. b Modified co-culture transmigration assay for HuCCT-1/
CAF and TFK-1/CAF treated with CSA or MPA. The used drug concentrations were 0.25 μM for CSA and 0.1 μM for MPA. *Non-treated co-culture vs.
monoculture: p <0.05, unpaired t-test
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Fig. 5 a. Fluorescence Western-blot for STAT3-, AKT- and ERK-pathways in CCA-cell line TFK-1. Cell-line in DMEM-media (a) and after stimulation
by conditioned CAF-media for 15 min (b). b Fluorescence Western-blot for STAT3-, AKT- and ERK-pathways in CCA-cell line HuCCT-1. Cell-line in
DMEM-media (a) and after stimulation by conditioned CAF-media for 15 min (b)
Fig. 6 a. Fluorescence Western-blot after treatment of the TFK-1 tumour cell line by Everolimus. Fluorescence Western-blot was processed after
treatment with Everolimus for 24 h and a following stimulation by conditioned CAF-media and 100 ng/mL hIL6 in 0 % FCS DMEM for 15 min ((a):
cell-line in DMEM-media, (b): treatment with 10 nM Everolimus, (c): treatment with 1 μM Everolimus). b. Fluorescence Western-blot after treatment
of the HuCCT-1 tumour cell line by Everolimus. Fluorescence Western-blot was processed after treatment with Everolimus for 24 h and a following
stimulation by conditioned CAF-media and 100 ng/mL hIL6 in 0 % FCS DMEM for 15 min ((a): cell-line in DMEM-media, (b): treatment with 10 nM
Everolimus, (c): treatment with 1 μM Everolimus)
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avoided, into anti-cancer treatment protocols in the sys-
temic treatment of recurrent malignancies after solid
organ transplantation.
In this study we were able to show that the immuno-
suppressive drugs Everolimus and especially MPA, have
an inhibitory effect on proliferation of CCA tumour
cells. The strong antiproliferative effect of MPA was seen
for both tumour cell lines. Previously, other groups re-
ported similar effects in cell lines derived from other
cancer types including multiple myeloma, leukemia,
lymphoma, Walker’s carcinosarcoma, glioblastoma, pan-
creatic, lung and colon [26–30]. These groups reported
a strong significant antiproliferative effect following
MPA-treatment [26–31, 37] and less significant antipro-
liferative effects for mTOR-inhibitor-treatment [14, 15].
For Everolimus antiproliferative effect was attenuated
after 96 h compared to shorter duration of treatment.
This observed effect might be related to the half-life of
this drug, which is known to be 30 h.
Both CCA cell-lines revealed enhanced migration
under co-culture conditions with CAFs, similar to other
tumour cells of different cancer types [34, 38–45]. It is
well known, that CAFs promote tumour progression
through the secretion of various growth factors and cy-
tokines leading to paracrine activation of numerous
intracellular signalling pathways [46]. After stimulation
of the TFK-1 cell line by conditioned CAF-media we ob-
served increased phosphorylation of STAT3, AKT and
ERK in the Western blot analysis. In contrast condi-
tioned CAF-media stimulation of HuCCT-1 cell line
only resulted in activation of the JAK/STAT3-pathway.
These findings are consistent with a previous study, in
which activation of STAT3 by CAFs-secreted IL-22 was
demonstrated in gastric cancer cells [47]. However, an-
other study showed activation of PI3K/AKT and MAPK/
ERK in the presence of CAFs [48]. Furthermore, a study
group from Japan demonstrated activation of ERK1/2
and AKT pathways by conditioned media from hepatic
stellate cell cultures in cultured HuCCT-1 cells [45]. The
observed lack of activation of the AKT and ERK-
pathways by conditioned CAF-media in the HuCCT-1
cell line in this study compared to other studies might
be related to differences in the secretion profile of the
tumour supporting cell. The growth stimulatory prop-
erty of supporting cells may vary depending on the cel-
lular phenotype (CAFs vs. stellate cells) and the tissue
type the supporting cell is derived from (bile duct vs.
hepatic). Alternatively, observed higher proliferative
activity of HuCCT-1 cell line and consequent higher
metabolism might result in a higher degradation of the
drug.
Treatment with Everolimus revealed significant inhib-
ition of CAF-mediated tumour cell migration. In con-
trast no inhibitory effect on migration was observed
with MPA treatment. The difference in the migratory re-
sponse between the two drugs may be due to the differ-
ing mechanisms by which they exert their effects.
Everolimus targets mTORC1 actions which primarily
lead to inhibition of cell cycle progression, survival, and
angiogenesis. MPA mainly inhibits proliferation via
inhibition of the synthesis of guanosine nucleotides
[19–22] and G1/S transition in the nucleus. A pos-
sible explanation for the ineffective inhibition of
tumour cell migration by MPA might be due to a
lack of inhibition of secretion of tumour cell stimulat-
ing cytokines after 30 h.
One mechanism by which tumour cell migration is
inhibited is likely to be due to direct inhibition of the
JAK/Stat3 pathway in CCA cells, which is primarily
inhibited by Everolimus, even in conditioned CAF-media.
Fig. 7 Densitometric measurement of cytokine expression by CCA-CAFs. CAFs treated with 1 μM Everolimus for 10 min show a significant lower
cytokine expression compared to non-treated CAFs (p <0.05, unpaired t-test)
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Furthermore, it has been demonstrated by several studies
that mTOR is a positive regulator of the JAK/STAT3-
pathway by phosphorylation of STAT3β [49–51]. There-
fore, the observed lower STAT3-activation could be a
result of a reduced phosphorylation of STAT3β by the
inhibited mTOR. The absence of an inhibition of the
ERK-phosphorylation following an mTOR-inhibition is
consistent with current literature [52, 53].
A second mechanism of inhibition of tumour cell mi-
gration is alluded to by the higher sensitivity to inhib-
ition by Everolimus in the co-culture experiments. A
reduction in migration is observed at concentrations of
Everolimus which are 2000 fold less than the concentra-
tion required to reduced JAK/Stat3 phosphorylation. It
is possible that cross-talk between CAFs and tumour
cells leads to an additive or synergistic effect in pro-
moting migration and this cross-talk is inhibited at
the lower concentrations of Everolimus treatment.
This notion is supported by the fact that CAF-cytokine se-
cretion was significantly inhibited under Everolimus treat-
ment. A reduced cytokine-expression by Everolimus
treated CAFs was recently also described for endometrial
cancer [48].
The measured cytokines in our study are known to pro-
mote tumour cell proliferation, −invasion and induce an
inflammatory tumour-microenvironment. IL-13, MCP-1
and MIF have been shown to induce infiltration of im-
mune cells and promote tumour progression, −invasion
and metastasis in various cancers [54–65]. MIF, known to
promote tumourigenesis by inhibiting the classic tumour
suppressor gene p53 [64], also stimulates the expression
of proinflammatory cytokines TNFα, interferon-γ, inter-
leukin 1β, interleukin 6, and interleukin 8 in a positive
feedback circuit [64] and therefore leads to an activa-
tion of several tumour-promoting pathways. Other
important cytokines, which were significantly inhibited
by Everolimus and are known to promote tumour-
progression and migration via the PI3K-AKT-, JAK/STAT-
and MAPK-pathways are IL-8 and Serpin E1. Serpin E1
also known as Plasminogen activator inhibitor-1 (PAI-1)
regulates cell migration by modulating the pericellular
proteolytic microenvironment by the JAK/STAT1 signal-
ling pathway [66]. The cytokine IL-8 promotes the growth
of various tumour types including colon, multiple mye-
loma and non-small cell lung cancers [67, 68]. Previous
studies showed that IL-8 can trigger PI3K and MAPK
pathways and induce proliferation of endothelial and non-
small cell lung cancer cells [69, 70]. Assuming that CAF-
secreted cytokines directly influence tumour-progression
and migration and that Everolimus treatment leads to an
inhibition of the CAFs’ cytokine-secretion in addition to
the direct tumour cell inhibition highlights the promising
therapeutic strategy utilizing Everolimus in the treatment
of CCA.
One of the major advantages of this study is that we
were able to isolate and cultivate α-SMA-positive CAFs
from resected CCA-tumours. Previous studies [17] used
stromal cells derived from non-CCA tissues. On the
other hand, these isolated CAFs were more fragile and
showed a compromised proliferative activity after a few
passages in-vitro. One possible reason for this observa-
tion might be a higher age of the donors. Consequently,
use of these CAFs for research is limited and cultivation
of CAFs generated from different tumours is needed.
Therefore, one bias could be a different biological behav-
iour of the used CAFs generated from different CCA-
tumours.
Conclusions
In conclusion we showed an antiproliferative effect of
MPA and Everolimus on tumour-cell-proliferation in
both CCA cell-lines. Secretion of proinflammatory cyto-
kines by CAFs associated with activation of JAK/STAT3-,
ERK- and AKT-signalling is likely be one of the major fac-
tors leading to increased migration of CCA-cells in co-
culture. Treatment of CCA-cells with Everolimus partly
inhibited JAK/STAT3-signaling. Furthermore, we were
able to significantly reduce CAF-cytokine secretion of the
tumour cell stimulating cytokines IL 8, IL 13, MCP1, MIF
and Serpin E1 by the treatment with Everolimus. We
propose chemotherapy in combination with Everolimus
after liver transplantation as a promising therapy option
for CCA.
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